0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Early-Onset Hearing Loss in Mouse Models of Alzheimer’s Disease and Increased DNA Damage in the Cochlea

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is considerable interest in whether sensory deficiency is associated with the development of Alzheimer’s disease (AD). Notably, the relationship between hearing impairment and AD is of high relevance but still poorly understood. In this study, we found early-onset hearing loss in two AD mouse models, 3xTgAD and 3xTgAD/Polβ +/−. The 3xTgAD/Polβ +/− mouse is DNA repair deficient and has more humanized AD features than the 3xTgAD. Both AD mouse models showed increased auditory brainstem response (ABR) thresholds between 16 and 32 kHz at 4 weeks of age, much earlier than any AD cognitive and behavioral changes. The ABR thresholds were significantly higher in 3xTgAD/Polβ +/− mice than in 3xTgAD mice at 16 kHz, and distortion product otoacoustic emission signals were reduced, indicating that DNA damage may be a factor underlying early hearing impairment in AD. Poly ADP-ribosylation and protein expression levels of DNA damage markers increased significantly in the cochlea of the AD mice but not in the adjacent auditory cortex. Phosphoglycerate mutase 2 levels and the number of synaptic ribbons in the presynaptic zones of inner hair cells were decreased in the cochlea of the AD mice. Furthermore, the activity of sirtuin 3 was downregulated in the cochlea of these mice, indicative of impaired mitochondrial function. Taken together, these findings provide new insights into potential mechanisms for hearing dysfunction in AD and suggest that DNA damage in the cochlea might contribute to the development of early hearing loss in AD.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          Ageing as a risk factor for neurodegenerative disease

          Ageing is the primary risk factor for most neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD). One in ten individuals aged ≥65 years has AD and its prevalence continues to increase with increasing age. Few or no effective treatments are available for ageing-related neurodegenerative diseases, which tend to progress in an irreversible manner and are associated with large socioeconomic and personal costs. This Review discusses the pathogenesis of AD, PD and other neurodegenerative diseases, and describes their associations with the nine biological hallmarks of ageing: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem cell exhaustion and altered intercellular communication. The central biological mechanisms of ageing and their potential as targets of novel therapies for neurodegenerative diseases are also discussed, with potential therapies including NAD+ precursors, mitophagy inducers and inhibitors of cellular senescence.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

            The defining features of Alzheimer disease (AD) include conspicuous changes in both brain histology and behavior. The AD brain is characterized microscopically by the combined presence of 2 classes of abnormal structures, extracellular amyloid plaques and intraneuronal neurofibrillary tangles, both of which comprise highly insoluble, densely packed filaments. The soluble building blocks of these structures are amyloid-β (Aβ) peptides for plaques and tau for tangles. Amyloid-β peptides are proteolytic fragments of the transmembrane amyloid precursor protein, whereas tau is a brain-specific, axon-enriched microtubule-associated protein. The behavioral symptoms of AD correlate with the accumulation of plaques and tangles, and they are a direct consequence of the damage and destruction of synapses that mediate memory and cognition. Synapse loss can be caused by the failure of live neurons to maintain functional axons and dendrites or by neuron death. During the past dozen years, a steadily accumulating body of evidence has indicated that soluble forms of Aβ and tau work together, independently of their accumulation into plaques and tangles, to drive healthy neurons into the diseased state and that hallmark toxic properties of Aβ require tau. For instance, acute neuron death, delayed neuron death following ectopic cell cycle reentry, and synaptic dysfunction are triggered by soluble, extracellular Aβ species and depend on soluble, cytoplasmic tau. Therefore, Aβ is upstream of tau in AD pathogenesis and triggers the conversion of tau from a normal to a toxic state, but there is also evidence that toxic tau enhances Aβ toxicity via a feedback loop. Because soluble toxic aggregates of both Aβ and tau can self-propagate and spread throughout the brain by prionlike mechanisms, successful therapeutic intervention for AD would benefit from detecting these species before plaques, tangles, and cognitive impairment become evident and from interfering with the destructive biochemical pathways that they initiate.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.

              To provide updated estimates of Alzheimer disease (AD) dementia prevalence in the United States from 2010 through 2050. Probabilities of AD dementia incidence were calculated from a longitudinal, population-based study including substantial numbers of both black and white participants. Incidence probabilities for single year of age, race, and level of education were calculated using weighted logistic regression and AD dementia diagnosis from 2,577 detailed clinical evaluations of 1,913 people obtained from stratified random samples of previously disease-free individuals in a population of 10,800. These were combined with US mortality, education, and new US Census Bureau estimates of current and future population to estimate current and future numbers of people with AD dementia in the United States. We estimated that in 2010, there were 4.7 million individuals aged 65 years or older with AD dementia (95% confidence interval [CI] = 4.0-5.5). Of these, 0.7 million (95% CI = 0.4-0.9) were between 65 and 74 years, 2.3 million were between 75 and 84 years (95% CI = 1.7-2.9), and 1.8 million were 85 years or older (95% CI = 1.4-2.2). The total number of people with AD dementia in 2050 is projected to be 13.8 million, with 7.0 million aged 85 years or older. The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed.
                Bookmark

                Author and article information

                Journal
                9918539786906676
                52268
                Aging Biol
                Aging Biology
                13 March 2024
                2024
                20 February 2024
                18 March 2024
                : 1
                : 20240025
                Affiliations
                [1 ]DNA repair Section, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
                [2 ]National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA
                [3 ]Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA
                [4 ]Waitt Advanced Biophotonics Center, Salk Institute for Biological Studies, La Jolla, CA, USA
                [5 ]Department of Cell & Developmental Biology School of Biological Sciences University of California, San Diego, La Jolla, CA, USA
                [6 ]Computational Biology & Genomics Core, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
                [7 ]Danish Center for Healthy Aging, University of Copenhagen, Copenhagen N, Denmark
                Author notes

                Author Contributions

                J.-H.P., V.A.B., and D.L.C. conceived and designed the study. J.-H.P. performed the measurements of ABR and DPOAE, and data analysis and wrote the article. B.D.S., K.P., and X.C. performed experiments for ELISA and qPCR analysis, and contributed to the interpretation of the data. J.-H.P., D.L.C., and M.G. collected mouse tissues. M.G., K.I., L.S., and E.C. performed cochlea dissection, whole-mount cochlea staining, and contributed to image acquisition. M.N.O. and W.C. contributed to constructive discussions for data analysis. J.-H.P., U.M., V.A.B., and D.L.C. edited the article and contributed to the interpretation of the results. All authors read and approved the final article.

                [* ]Corresponding author: vbohr@ 123456sund.ku.dk
                Article
                NIHMS1971152
                10.59368/agingbio.20240025
                10948084
                38500536
                db269595-1797-4af4-b574-bae167c61819

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                Comments

                Comment on this article